



An extended analysis of RESONATE-2 to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia

 **269** Patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) (age ≥ 65 years)



End-points

Median progression-free survival	not reached	15 months HR 0.12; 95% CI, 0.07-0.20; $P < .0001$
24-month progression-free survival	89 %	49 %
24-month overall survival	95 %	84 % HR 0.432; 95% CI, 0.21-0.86; $P < .0145$
Overall response rate	92%	
Complete remission	18%	
Quality of life: FACIT fatigue	63%	53 % Odds ratio, 1.50; 95% CI, 0.92-2.45; $P = .0013$
Safety	<p>Frequent AEs: Diarrhea, fatigue, cough, anemia, and nausea</p> <p>Grade ≥ 3 AEs: Neutropenia (12%), anemia (7%), hypertension (5%)</p>	

First-line treatment with ibrutinib results in long-term PFS in patients with CLL and the response quality continues to improve with ibrutinib over time with substantial increased in patients achieving complete remission